Saxenda Approval History
- FDA approved: Yes (First approved December 23rd, 2014)
- Brand name: Saxenda
- Generic name: liraglutide
- Dosage form: Injection
- Company: Novo Nordisk
- Treatment for: Obesity
Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.
Development History and FDA Approval Process for Saxenda
|Dec 23, 2014||FDA Approves Saxenda (liraglutide [rDNA origin] injection) for Obesity|
|Sep 11, 2014||FDA Advisory Committee Votes 14-1 in Favor of Saxenda (liraglutide) for Obesity|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.